Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| But we do feel like the patient pipeline is solid and has been demonstrating good consistency there |
| As you saw in the fourth quarter press release issued earlier today, the NeuroPace team has continued to execute on our strategy and delivered another strong quarter to cap off what has been an outstanding year |
| We are pleased with the momentum of these efforts within our Level 4 centers, and it has driven much of our RNS system growth in 2023 |
| Market development plans here initiated with Project CARE, our indication expansion plans for the RNS System with idiopathic epilepsy with NAUTILUS and then the incremental expansion of the commercial organization that I mentioned along with demonstrating operating discipline and a strong cash position |
| We are very excited by the progress we've been making over the past year at NeuroPace |
| As we look back to where the company was just a year ago, we’ve continually raised the bar and exceeded expectations |
| I am proud of everyone on the team and all that was accomplished in 2023 and look forward to capitalizing on this momentum in 2024 |
| Consistent with our 2024 guidance we believe we are positioned to achieve 2024 revenue of between $73 million to $77 million, and are also positioned to accelerate our growth in the future as these opportunities develop |
| We’re really pleased with how that has gone and how that is going |
| So we think as we look into the future, we believe this positions us to accelerate our growth as well |
| We're excited about 2024 in the strategies and plans that we've got for the year |
| We're excited about Project CARE |
| With regard to competitive dynamics, I think we feel like we're in a very good competitive position |
| But I think with regard to market dynamics we feel like we're in a strong position as it relates to both clinical data as well as the technology differentiation and feel like we're in a good position from a competitive dynamic perspective there |
| We think there's a number of really good opportunities in front of us as well as some challenges, but we're excited about the year in the plans that we've got for the year |
| We've got differentiated technology and data, growth in our core business and our distributed products |
| This study has the potential to represent a highly meaningful market expansion opportunity |
| Also, we continue to see revenue growth from our exclusive partnership with DIXI Medical to market and sell their diagnostic electrodes and related products for epilepsy |
| Obviously, you guys had a very nice year in 2023 with 44% growth, did a nice job of keeping expectations in check throughout the year |
| And I think sometimes doesn’t get quite the billing that it should, from a differentiation perspective is we are uniquely able to monitor record and then analyze data, brain activity and increasingly, our ability to analyze that information we feel like has the potential to provide insights, both for our core business as well as in other areas here potentially like report |
| As we review our performance, we continue to be pleased with the progress made in 2023 |
| But bottom line, you’re feeling good about growing off like around the $52 million you did in initial implants for 2023 |
| The modern RNS story also involves highlighting the improvements in ease of use and efficiency we have made with the RNS platform |
| So we think we've got some clear opportunities in front of us that we're excited about |
| And when we think about the opportunities that are out there, we do think that, so we’re excited about this |
| In support of the growth that we have seen with the RNS system and Level 4 centers, as well as in order to ensure the proper support for Project CARE, we have begun making incremental additions to our sales and support teams and are pleased with the skill sets and experiences of the representatives we have hired and that we are seeing express interest in joining the NeuroPace team |
| As a result, we have been able to execute our commercial strategy while maintaining disciplined expense management, resulting in cash burn in the fourth quarter of 2023 of $3.4 million, compared to $7.9 million in the fourth quarter of 2022 |
| And so we’ve been really pleased with the progress that we’ve made with DIXI, but I also see opportunities in a number of different kind of vectors there to leverage the distribution relationship in our organization to broaden the adoption and utilization of DIXI as well as with RNS |
| We believe that our strategy is clear and that our opportunities are compelling |
| Looking forward, looking at 12% to 18% growth, looks like pretty solid growth |
| Statement |
|---|
| The placement implant revenue continued to decline compared to the same period last year and represented approximately 4% of total revenue |
| And we think portend well and then some challenges to overcome as well, but we've rolled that all into the guidance as well |
| As I've mentioned on previous calls, we expected this decline to occur as most patients with the older version of the RNS device have already had their devices replaced with the newer version |
| Loss from operations was $5.1 million in the fourth quarter of 2023 compared with $9.9 million in the prior year period |
| The increase in RNS gross margin was partially offset by the lower gross margin from distribution of DIXI Medical products |
| Net loss was $6.2 million for the fourth quarter of 2023 compared with $11.1 million in the fourth quarter of 2022 |
| And as I mentioned, when you see the growth that’s in the guidance, that growth has to overcome the impact of the NAUTILUS implants in 2023, the net change of the further diminishment of the replacement units and then that DIXI impact of full year distribution |
Please consider a small donation if you think this website provides you with relevant information